UniProtKB/Swiss-Prot Q13351: Variant p.Thr334Arg

Krueppel-like factor 1
Gene: KLF1
Feedback?

Variant information Variant position:

334 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Threonine (T) to Arginine (R) at position 334 (T334R, p.Thr334Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (T) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Polymorphism:

Genetic variations in KLF1 underlie the fetal hemoglobin quantitative trait locus 6 (HBFQTL6) [MIM:613566]. Classic hereditary persistence of fetal hemoglobin (HPFH) is characterized by a substantial elevation of fetal hemoglobin (HbF) in adult red blood cells. There are no other phenotypic or hematologic manifestations. In healthy adults, fetal hemoglobin (HbF) is present at residual levels (less than 0.06% of total hemoglobin) with over 20-fold variation. Ten to fifteen percent of adults fall within the upper tail of the distribution.Genetic variations in KLF1 underlie the blood group-Lutheran inhibitor (In(Lu)) phenotype [MIM:111150]; also known as dominant Lu (a-b-) phenotype. In(Lu) is characterized phenotypically by the apparent absence of the Lu antigen (BCAM) on red blood cells during serologic tests: Lu(a-b-). - Additional information on the polymorphism described.
Other resources:

Links to websites of interest for the variant.

Variant rs483352841 [ dbSNP | Ensembl ]

Sequence information Variant position:

334 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

362 The length of the canonical sequence.
Location on the sequence:

EGCGWRFARSDELTRHYRKH T GQRPFRCQLCPRAFSRSDHL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         EGCGWRFARSDELTRHY---------RKHTG-QRPFR------------------CQL-------CPRAFS-------------RSDHL

Mouse                         DGCDWRFARSDELTRHY---------RKHTG-HRPFC----

Zebrafish                     DGCGWKFARSDELTRHF---------RKHTG-QKPYE----

Caenorhabditis elegans        DGCDWRFARSDELTRHY---------RKHTG-DRPFK----

Fission yeast                 DDSEVSIKHAVDMVEAFLGGDMEYDVQNETGLHRPWCLYVS

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 362	Krueppel-like factor 1

Literature citations
KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of beta-thalassemia.
Liu D.; Zhang X.; Yu L.; Cai R.; Ma X.; Zheng C.; Zhou Y.; Liu Q.; Wei X.; Lin L.; Yan T.; Huang J.; Mohandas N.; An X.; Xu X.;
Blood 124:803-811(2014)
Cited for: VARIANTS LYS-5; PRO-298; ASP-299; ARG-334 AND TYR-341;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.